Outlook for the Indian Pharma Industry remains stable for this year
The stability is led by healthy demand in the domestic and emerging markets
The stability is led by healthy demand in the domestic and emerging markets
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Subscribe To Our Newsletter & Stay Updated